Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma

Ceftriaxone‐induced immune hemolytic anemia (CIHA) is the second most common cause of drug‐induced hemolytic anemia. Prompt recognition of this drug reaction is essential because brisk hemolysis can be deadly. The extent to which ceftriaxone antibodies persist after CIHA is unknown; rechallenging pa...

Full description

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 63; no. 10; pp. 1852 - 1855
Main Authors Pecker, L. H., Timsar, A., Pary, P. P., Denomme, G. A., Criss, V. R., Luban, N. L. C., Hwang, E. I., Wong, E. C. C.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.10.2016
Wiley Subscription Services, Inc
Subjects
Anemia
Anemia, Hemolytic, Autoimmune - chemically induced
anemias
Anti-Bacterial Agents - adverse effects
Antibodies - blood
blood bank
Brain Neoplasms - immunology
Ceftriaxone - adverse effects
Ceftriaxone - immunology
Child, Preschool
Female
Glioma - immunology
Hematology
Humans
immune cytopenias
Oncology
Pediatrics
transfusion medicine
transfusion medicine
anemias
blood bank
immune cytopenias
Online AccessGet full text

Cover

More Information
Summary:Ceftriaxone‐induced immune hemolytic anemia (CIHA) is the second most common cause of drug‐induced hemolytic anemia. Prompt recognition of this drug reaction is essential because brisk hemolysis can be deadly. The extent to which ceftriaxone antibodies persist after CIHA is unknown; rechallenging patients who have experienced CIHA is not recommended. We report a case of CIHA in a neurooncology patient, which is the first to show anticeftriaxone antibodies with Rh specificity and persisted for 8 months after the drug reaction. These findings have implications for understanding the mechanism of CIHA.
Bibliography:National Center for Advancing Translational Sciences
National Institutes of Health - No. T32HL110841-04
ArticleID:PBC26101
istex:966B14474BE35FE804530BF66CCBBFB7DE12DB43
ark:/67375/WNG-H09GQT3C-H
Grant sponsor: National Center for Advancing Translational Sciences; Grant sponsor: National Institutes of Health; Grant number: T32HL110841‐04.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26101